My constant prayer since the start of the development of the COVID-19 vaccines has been that the knowledge gained would lead to an effective vaccine against malaria.
When I last checked the Johns Hopkins site, the total estimate of COVID-19 cases since we started keeping track have been a little less than 237 million. (Just how accurate that guess is, is another issue.)
In that time period, there have been approximately 382 million cases of malaria, a debilitating disease that cripples economies, and preferentially kills young children.
But there is good news. While there is still much room for new vaccine-development techniques to improve the situation, there is now a vaccine for malaria. It was developed by GlaxoSmithKline* and proven effective six years ago. Finally, after futher testing, has been given the green light for mass vaccinations in sub-Saharan Africa.
"Effective," in this case, is only 40%—I said there was room for improvement—and requires a series of four shots, given at five, six, seven, and 18 months of age. In a part of the world where health care is often less than stellar, I imagine this will be a challenge to implement. But malaria is a much trickier disease than, say, COVID ("comparing them is like comparing a person and a cabbage") and this is a huge milestone.